Patient‐reported outcomes after Tixagevimab and Cilgavimab pre‐exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk
Jennifer L. Alejo(Johns Hopkins University), William A. Werbel(Johns Hopkins University), Alexa Jefferis(Johns Hopkins University), Teresa Po‐Yu Chiang(Johns Hopkins University), Allan B. Massie(Johns Hopkins University), Robin K. Avery(Johns Hopkins University), Daniel Warren(Johns Hopkins University), Aaron A.R. Tobian(Johns Hopkins University), Andrew H. Karaba(Johns Hopkins University), Dorry L. Segev(New York University), Jake D. Kim(Johns Hopkins University)
Cited by 10
Related Papers
Foot strike patterns and collision forces in habitually barefoot versus shod runners
|Nature|2010|1.4k
Clinical Practice Guidelines From the AABB
|JAMA|2016|1.1k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
|JAMA|2021|1k
Deployment of convalescent plasma for the prevention and treatment of COVID-19
|Journal of Clinical Investigation|2020|863